Durvalumab with transarterial chemoembolization (TACE) is in clinical development for treating patients with locoregional hepatocellular carcinoma (HCC). HCC is the most common type of primary liver cancer, which affects men more than women, and is more likely to develop the older a person gets. Symptoms include weight loss, jaundice (yellowing of skin), itching, nausea (feeling sick), bloating of the abdomen, loss of appetite, feeling full after eating small amounts, abdomen pain and a lump on the right side of the abdomen.
Durvalumab with transarterial chemoembolisation for hepatocellular carcinoma
Durvalumab with transarterial chemoembolization (TACE) is in clinical development for treating patients with locoregional hepatocellular carcinoma (HCC). HCC is the most common type of primary liver cancer, which affects men more than women, and is more likely to develop the older a person gets.
Interventions:
Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)
, Transarterial Chemoembolisation (TACE)
Indications:
Hepatocellular carcinoma (HCC)
Therapeutic Areas:
Gastrointestinal Cancer
Year:
2022